Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IRIX 
IRIDEX Corporation (IRIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/29/2025: IRIX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -49.13% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.77M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) - | Beta 0.61 | 52 Weeks Range 0.78 - 2.41 | Updated Date 06/29/2025 |
52 Weeks Range 0.78 - 2.41 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.43 |
Earnings Date
Report Date 2025-06-18 | When After Market | Estimate -0.12 | Actual -0.1008 |
Profitability
Profit Margin -14.61% | Operating Margin (TTM) -1.72% |
Management Effectiveness
Return on Assets (TTM) -9.54% | Return on Equity (TTM) -106.93% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12829343 | Price to Sales(TTM) 0.3 |
Enterprise Value 12829343 | Price to Sales(TTM) 0.3 | ||
Enterprise Value to Revenue 0.26 | Enterprise Value to EBITDA -3.61 | Shares Outstanding 16789000 | Shares Floating 11118197 |
Shares Outstanding 16789000 | Shares Floating 11118197 | ||
Percent Insiders 27.93 | Percent Institutions 18.76 |
Upturn AI SWOT
IRIDEX Corporation
Company Overview
History and Background
IRIDEX Corporation was founded in 1989 and is focused on the development and marketing of laser-based medical systems, delivery devices and consumable instrumentation for the treatment of glaucoma, retinal diseases and other ophthalmic applications.
Core Business Areas
- Glaucoma: Develops and markets laser systems and single-use delivery devices for treating glaucoma, a leading cause of blindness.
- Retinal: Offers laser systems and delivery devices for treating retinal diseases such as diabetic retinopathy and macular degeneration.
Leadership and Structure
Dominique Beckers (CEO), and the company has a typical corporate structure with a board of directors and various departments including R&D, sales, and marketing.
Top Products and Market Share
Key Offerings
- Cyclo G6 Laser System: A laser system used for glaucoma treatment. It utilizes MicroPulse technology to reduce inflammation. Competitors include Lumenis and Ellex. Market share data not readily available without access to proprietary market reports.
- IQ 532 and IQ 577 Laser Systems: Retinal laser systems used to treat retinal diseases. These provide precision and control during surgery. Competitors include Topcon and Nidek. Market share data not readily available without access to proprietary market reports.
Market Dynamics
Industry Overview
The ophthalmic laser market is growing, driven by an aging population, increasing prevalence of diabetes, and advancements in laser technology.
Positioning
IRIDEX is a player in the ophthalmic laser market, focusing on glaucoma and retinal disease treatments. Its competitive advantage lies in its MicroPulse technology and specialized delivery devices.
Total Addressable Market (TAM)
The global ophthalmic laser market is estimated to be worth billions of dollars. IRIDEX is positioned to capture a share of this market through its specialized products. The exact TAM and IRIDEX's position require deeper market analysis.
Upturn SWOT Analysis
Strengths
- MicroPulse technology
- Specialized delivery devices
- Focus on glaucoma and retinal diseases
Weaknesses
- Limited financial resources compared to larger competitors
- Concentration in a specific niche market
- Reliance on a small number of key products
Opportunities
- Expanding into emerging markets
- Developing new applications for existing technologies
- Acquiring complementary technologies or companies
Threats
- Intense competition from larger medical device companies
- Technological obsolescence
- Changes in healthcare regulations and reimbursement policies
Competitors and Market Share
Key Competitors
- LENS
- ALGN
- COO
Competitive Landscape
IRIDEX competes with larger, more established companies in the ophthalmic market. It has competitive advantages in its specific product areas (MicroPulse), but faces challenges due to its smaller size and limited resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth can only be assessed by reviewing revenue and earnings growth from past financial statements.
Future Projections: Future projections are based on market analysis and analyst consensus estimates, which can be found on financial news websites and analyst reports.
Recent Initiatives: Recent initiatives are typically announced in press releases and investor presentations.
Summary
IRIDEX Corporation is a small player in the ophthalmic laser market with specialized products for glaucoma and retinal diseases. Its MicroPulse technology is a key strength, but it faces challenges due to competition from larger companies. The company needs to focus on expanding its market reach and developing new applications for its technologies. Monitoring its financials, competitor actions, and changes in the regulatory environment is crucial.
Similar Stocks
Sources and Disclaimers
Data Sources:
- SEC filings (10-K, 10-Q), company website, investor presentations, financial news articles, analyst reports.
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is based on estimates and may not be precise. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About IRIDEX Corporation
Exchange NASDAQ | Headquaters Mountain View, CA, United States | ||
IPO Launch date 1996-02-15 | CEO, President & Director Mr. Patrick Mercer | ||
Sector Healthcare | Industry Medical Devices | Full time employees 93 | Website https://www.iridex.com |
Full time employees 93 | Website https://www.iridex.com | ||
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.